248 related articles for article (PubMed ID: 32302351)
1. Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer.
Tutzauer J; Sjöström M; Bendahl PO; Rydén L; Fernö M; Leeb-Lundberg LMF; Alkner S
PLoS One; 2020; 15(4):e0231786. PubMed ID: 32302351
[TBL] [Abstract][Full Text] [Related]
2. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.
Sjöström M; Hartman L; Grabau D; Fornander T; Malmström P; Nordenskjöld B; Sgroi DC; Skoog L; Stål O; Leeb-Lundberg LM; Fernö M
Breast Cancer Res Treat; 2014 May; 145(1):61-71. PubMed ID: 24715381
[TBL] [Abstract][Full Text] [Related]
3. Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
Alkner S; Ehinger A; Bendahl PO; Rydén L; Fernö M
Eur J Cancer; 2015 Nov; 51(16):2304-13. PubMed ID: 26243193
[TBL] [Abstract][Full Text] [Related]
4. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer.
Ignatov A; Ignatov T; Weissenborn C; Eggemann H; Bischoff J; Semczuk A; Roessner A; Costa SD; Kalinski T
Breast Cancer Res Treat; 2011 Jul; 128(2):457-66. PubMed ID: 21607586
[TBL] [Abstract][Full Text] [Related]
5. G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen.
Ignatov T; Claus M; Nass N; Haybaeck J; Seifert B; Kalinski T; Ortmann O; Ignatov A
Breast Cancer Res Treat; 2019 Feb; 174(1):121-127. PubMed ID: 30478785
[TBL] [Abstract][Full Text] [Related]
6. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.
Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G
Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103
[TBL] [Abstract][Full Text] [Related]
7. GPR30-mediated HMGB1 upregulation in CAFs induces autophagy and tamoxifen resistance in ERα-positive breast cancer cells.
Liu L; Liu S; Luo H; Chen C; Zhang X; He L; Tu G
Aging (Albany NY); 2021 Jun; 13(12):16178-16197. PubMed ID: 34182538
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth.
Catalano S; Giordano C; Panza S; Chemi F; Bonofiglio D; Lanzino M; Rizza P; Romeo F; Fuqua SA; Maggiolini M; Andò S; Barone I
Breast Cancer Res Treat; 2014 Jul; 146(2):273-85. PubMed ID: 24928526
[TBL] [Abstract][Full Text] [Related]
9. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
10. GPER-1 expression is associated with a decreased response rate to primary tamoxifen therapy of breast cancer patients.
Ignatov T; Treeck O; Kalinski T; Ortmann O; Ignatov A
Arch Gynecol Obstet; 2020 Feb; 301(2):565-571. PubMed ID: 31900584
[TBL] [Abstract][Full Text] [Related]
11. Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.
Alkner S; Bendahl PO; Ehinger A; Lövgren K; Rydén L; Fernö M
PLoS One; 2016; 11(3):e0150977. PubMed ID: 26959415
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy.
Girgert R; Emons G; Gründker C
Breast Cancer Res Treat; 2012 Jul; 134(1):199-205. PubMed ID: 22290080
[TBL] [Abstract][Full Text] [Related]
13. GPER-1/GPR30 a novel estrogen receptor sited in the cell membrane: therapeutic coupling to breast cancer.
Molina L; Figueroa CD; Bhoola KD; Ehrenfeld P
Expert Opin Ther Targets; 2017 Aug; 21(8):755-766. PubMed ID: 28671018
[TBL] [Abstract][Full Text] [Related]
14. G protein-coupled estrogen receptor is apoptotic and correlates with increased distant disease-free survival of estrogen receptor-positive breast cancer patients.
Broselid S; Cheng B; Sjöström M; Lövgren K; Klug-De Santiago HL; Belting M; Jirström K; Malmström P; Olde B; Bendahl PO; Hartman L; Fernö M; Leeb-Lundberg LM
Clin Cancer Res; 2013 Apr; 19(7):1681-92. PubMed ID: 23554355
[TBL] [Abstract][Full Text] [Related]
15. GPER mediates decreased chemosensitivity via regulation of ABCG2 expression and localization in tamoxifen-resistant breast cancer cells.
Yu T; Cheng H; Ding Z; Wang Z; Zhou L; Zhao P; Tan S; Xu X; Huang X; Liu M; Peng M; Qiu YA
Mol Cell Endocrinol; 2020 Apr; 506():110762. PubMed ID: 32087276
[TBL] [Abstract][Full Text] [Related]
16. Continuous Exposure of Breast Cancer Cells to Tamoxifen Upregulates GPER-1 and Increases Cell Proliferation.
Molina L; Bustamante F; Ortloff A; Ramos I; Ehrenfeld P; Figueroa CD
Front Endocrinol (Lausanne); 2020; 11():563165. PubMed ID: 33117280
[TBL] [Abstract][Full Text] [Related]
17. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells.
Thomas P; Pang Y; Filardo EJ; Dong J
Endocrinology; 2005 Feb; 146(2):624-32. PubMed ID: 15539556
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
[TBL] [Abstract][Full Text] [Related]
19. GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer.
Arias-Pulido H; Royce M; Gong Y; Joste N; Lomo L; Lee SJ; Chaher N; Verschraegen C; Lara J; Prossnitz ER; Cristofanilli M
Breast Cancer Res Treat; 2010 Aug; 123(1):51-8. PubMed ID: 19902352
[TBL] [Abstract][Full Text] [Related]
20. Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis.
Chen Y; Li Z; He Y; Shang D; Pan J; Wang H; Chen H; Zhu Z; Wan L; Wang X
Toxicol Appl Pharmacol; 2014 Mar; 275(2):176-81. PubMed ID: 24440569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
